Victory Capital Management
SLDB icon

Victory Capital Management’s Solid Biosciences SLDB Stock Holding History

Victory Capital Management’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-782
Closed -$7K – 2767
2022
Q2 		$7K Buy
782
+12
+2% +$125 ﹤0.01% 2669
2022
Q1 		$6K Sell
770
-22
-3% -$388 ﹤0.01% 2701
2021
Q4 		$21K Sell
792
-24
-3% -$734 ﹤0.01% 2692
2021
Q3 		$29K Sell
816
-41
-5% -$1.74K ﹤0.01% 2715
2021
Q2 		$47K Buy
+857
New +$56.6K ﹤0.01% 2668
2020
Q2 		– Sell
-659
Closed -$24K – 3174
2020
Q1 		$24K Buy
+659
New +$32.6K ﹤0.01% 3037
2019
Q4 		– Sell
-123
Closed -$19K – 3186
2019
Q3 		$19K Buy
+123
New +$13.9K ﹤0.01% 3069

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Victory Capital Management's SLDB Position: Q3 2022 in Review

Victory Capital Management sold out of Solid Biosciences (SLDB) in Q3 2022, closing a stake of 782 shares — an estimated $7K sold.

Victory Capital Management first reported a position in SLDB in Q3 2019 and held it in 7 quarters. The position peaked at $47K in Q2 2021. 58 funds tracked by Wall St. Rank hold SLDB as of Q3 2022.

  • Victory Capital Management reported no remaining Solid Biosciences position as of Q3 2022 after selling out during the quarter.
  • Victory Capital Management sold 782 Solid Biosciences shares in Q3 2022, an estimated $7K.
  • Victory Capital Management first reported a position in Solid Biosciences in Q3 2019 and held it in 7 quarters.
  • Victory Capital Management's Solid Biosciences position peaked at $47K in Q2 2021.
  • 58 funds tracked by Wall St. Rank held Solid Biosciences as of Q3 2022.

Based on Victory Capital Management's 13F filing for Q3 2022, filed 2 Nov 2022.